Skip to main content

Folliculogenesis

3
Pipeline Programs
3
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Neurocrine Biosciences
1 program
1
ElagolixPhase 11 trial
Active Trials
NCT01403038Completed216Est. Nov 2012
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ElagolixPhase 1
Abbott
AbbottABBOTT PARK, IL
1 program
1
ElagolixPhase 1

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Neurocrine BiosciencesElagolix

Clinical Trials (1)

Total enrollment: 216 patients across 1 trials

An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

Start: Jun 2011Est. completion: Nov 2012216 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.